Lonza Group AG (LZAGY)
| Previous close | 56.64 |
| Open | 57.65 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 57.33 - 57.84 |
| 52-week range | 34.19 - 66.00 |
| Volume | |
| Avg. volume | 103,750 |
| Market cap | 41.402B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | 59.19 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.39 (0.68%) |
| Ex-dividend date | 09 May 2023 |
| 1y target est | N/A |
- PR Newswire
NeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
- PR Newswire
ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products
Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces a licensing agreement to develop bispecific ADCs with ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases.
- Business Wire
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
